Board Approves $1B Share Repurchase Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy WST?
On February 17, the Board of Directors authorized a new share repurchase program for the purchase of up to $1B of the company's common stock. The company's previous share repurchase program was fully utilized prior to its December 31, 2025, expiration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 233.830
Low
285.00
Averages
348.70
High
375.00
Current: 233.830
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Centene Shares Drop 7.7%, Worst Performer in S&P 500 Today
- Poor Stock Performance: Centene's shares fell 7.7% today, making it the worst performer in the S&P 500, reflecting market concerns about its future growth prospects, which could impact investor confidence.
- Year-to-Date Review: Year-to-date, Centene's performance is down approximately 2.8%, indicating challenges in the competitive healthcare market, potentially leading investors to reassess their investment strategies.
- Market Dynamics Analysis: In contrast to Centene, West Pharmaceutical Services also dropped 7.7%, while Western Digital rose 5.6%, highlighting differing market reactions to various companies, which may influence investor asset allocation decisions.
- Investor Sentiment Fluctuation: Today's stock price volatility may raise doubts among investors regarding Centene's future performance, especially against the backdrop of multiple challenges facing the healthcare industry, potentially prompting more investors to seek other investment opportunities with greater growth potential.
See More
West Pharmaceutical CEO Eric Green Plans Retirement, Transition Expected by 2026
- Executive Retirement Plan: West Pharmaceutical's CEO Eric Green plans to retire after a successor is found, ensuring a smooth leadership transition expected in the second half of 2026, highlighting the company's commitment to stable growth.
- New CEO Recruitment: The company has engaged a leading executive recruiting firm to assist in finding a successor, indicating a rigorous approach to executive selection that may influence future strategic direction and market confidence.
- Performance Guidance Reaffirmed: West Pharmaceutical reaffirmed its guidance for Q1 and full-year 2026, expecting adjusted earnings per share between $1.65 and $1.70, reflecting a year-over-year growth of 13% to 16.4%, demonstrating the company's robust market performance.
- Sales Growth Expectations: The company anticipates Q1 2026 net sales between $770 million and $790 million, representing a year-over-year growth of 10.3% to 13.2%, which not only reflects strong market demand but also lays a solid foundation for the company's future financial health.
See More
West Pharmaceutical CEO Eric Green Plans Retirement After Succession
- CEO Retirement Announcement: West Pharmaceutical Services' President and CEO Eric M. Green has informed the board of his retirement plans, expected to take effect in the second half of 2026 after a successor is appointed, which may impact the company's strategic direction and leadership stability.
- Leadership Transition Strategy: The company has engaged an executive recruiting firm to assist in the search for a successor, indicating proactive measures to ensure a smooth leadership transition that could maintain investor confidence and market stability.
- Financial Guidance Reaffirmation: West Pharmaceutical reaffirmed its financial guidance announced on February 12, 2026, targeting 5% to 7% organic revenue growth, reflecting confidence in accelerating high-value product (HVP) demand, which may drive future performance growth.
- Market Reaction: Following the announcement, West Pharmaceutical's stock price rose slightly by 0.04% in after-hours trading to $248.17, indicating a cautiously optimistic market sentiment regarding the company's future developments.
See More
West Pharmaceutical CEO Eric Green Announces Retirement
- Leadership Transition: Eric Green, CEO of West Pharmaceutical Services, plans to retire after a successor is appointed, ensuring a smooth leadership transition expected in the second half of 2026, highlighting the company's commitment to sustained growth.
- Remarkable Performance: Under Green's leadership, the company doubled its sales to $3.07 billion in fiscal year 2025, achieving a total shareholder return of approximately 350%, which not only reflects strong growth but also sets a solid foundation for future leadership.
- Innovation and Pandemic Response: During Green's tenure, West drove innovations that addressed patient needs and played a crucial role in supporting vaccine delivery during the COVID-19 pandemic, showcasing the company's importance in responding to major public health challenges.
- Future Potential: With over 10,000 employees and 25 manufacturing facilities globally, West has the capacity to deliver over 41 billion components annually, demonstrating its strong potential to achieve long-term growth ambitions.
See More
West Pharmaceutical CEO Eric Green Announces Retirement Plans
- Leadership Transition: Eric Green, CEO of West Pharmaceutical Services, plans to retire once a successor is found, ensuring a smooth transition expected in the second half of 2026, which will provide new perspectives and direction for the company's future leadership.
- Remarkable Performance Review: Under Green's tenure, the company doubled its sales and achieved a total shareholder return of approximately 350%, reflecting strong growth during his leadership and laying a solid foundation for future strategic development.
- Innovation and Crisis Response: Green's leadership saw the company drive innovations, particularly in supporting global vaccine delivery during the COVID-19 pandemic, showcasing West's adaptability and market impact during crises.
- Future Outlook: With over 10,000 employees and 25 manufacturing facilities worldwide, West generated $3.07 billion in net sales in fiscal year 2025, demonstrating its leadership in high-quality injectable solutions and positioning for continued value creation.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Centene Shares Drop 7.7%, Worst Performer in S&P 500 Today
- Poor Stock Performance: Centene's shares fell 7.7% today, making it the worst performer in the S&P 500, reflecting market concerns about its future growth prospects, which could impact investor confidence.
- Year-to-Date Review: Year-to-date, Centene's performance is down approximately 2.8%, indicating challenges in the competitive healthcare market, potentially leading investors to reassess their investment strategies.
- Market Dynamics Analysis: In contrast to Centene, West Pharmaceutical Services also dropped 7.7%, while Western Digital rose 5.6%, highlighting differing market reactions to various companies, which may influence investor asset allocation decisions.
- Investor Sentiment Fluctuation: Today's stock price volatility may raise doubts among investors regarding Centene's future performance, especially against the backdrop of multiple challenges facing the healthcare industry, potentially prompting more investors to seek other investment opportunities with greater growth potential.
See More
West Pharmaceutical CEO Eric Green Plans Retirement, Transition Expected by 2026
- Executive Retirement Plan: West Pharmaceutical's CEO Eric Green plans to retire after a successor is found, ensuring a smooth leadership transition expected in the second half of 2026, highlighting the company's commitment to stable growth.
- New CEO Recruitment: The company has engaged a leading executive recruiting firm to assist in finding a successor, indicating a rigorous approach to executive selection that may influence future strategic direction and market confidence.
- Performance Guidance Reaffirmed: West Pharmaceutical reaffirmed its guidance for Q1 and full-year 2026, expecting adjusted earnings per share between $1.65 and $1.70, reflecting a year-over-year growth of 13% to 16.4%, demonstrating the company's robust market performance.
- Sales Growth Expectations: The company anticipates Q1 2026 net sales between $770 million and $790 million, representing a year-over-year growth of 10.3% to 13.2%, which not only reflects strong market demand but also lays a solid foundation for the company's future financial health.
See More
West Pharmaceutical CEO Eric Green Plans Retirement After Succession
- CEO Retirement Announcement: West Pharmaceutical Services' President and CEO Eric M. Green has informed the board of his retirement plans, expected to take effect in the second half of 2026 after a successor is appointed, which may impact the company's strategic direction and leadership stability.
- Leadership Transition Strategy: The company has engaged an executive recruiting firm to assist in the search for a successor, indicating proactive measures to ensure a smooth leadership transition that could maintain investor confidence and market stability.
- Financial Guidance Reaffirmation: West Pharmaceutical reaffirmed its financial guidance announced on February 12, 2026, targeting 5% to 7% organic revenue growth, reflecting confidence in accelerating high-value product (HVP) demand, which may drive future performance growth.
- Market Reaction: Following the announcement, West Pharmaceutical's stock price rose slightly by 0.04% in after-hours trading to $248.17, indicating a cautiously optimistic market sentiment regarding the company's future developments.
See More
West Pharmaceutical CEO Eric Green Announces Retirement
- Leadership Transition: Eric Green, CEO of West Pharmaceutical Services, plans to retire after a successor is appointed, ensuring a smooth leadership transition expected in the second half of 2026, highlighting the company's commitment to sustained growth.
- Remarkable Performance: Under Green's leadership, the company doubled its sales to $3.07 billion in fiscal year 2025, achieving a total shareholder return of approximately 350%, which not only reflects strong growth but also sets a solid foundation for future leadership.
- Innovation and Pandemic Response: During Green's tenure, West drove innovations that addressed patient needs and played a crucial role in supporting vaccine delivery during the COVID-19 pandemic, showcasing the company's importance in responding to major public health challenges.
- Future Potential: With over 10,000 employees and 25 manufacturing facilities globally, West has the capacity to deliver over 41 billion components annually, demonstrating its strong potential to achieve long-term growth ambitions.
See More
West Pharmaceutical CEO Eric Green Announces Retirement Plans
- Leadership Transition: Eric Green, CEO of West Pharmaceutical Services, plans to retire once a successor is found, ensuring a smooth transition expected in the second half of 2026, which will provide new perspectives and direction for the company's future leadership.
- Remarkable Performance Review: Under Green's tenure, the company doubled its sales and achieved a total shareholder return of approximately 350%, reflecting strong growth during his leadership and laying a solid foundation for future strategic development.
- Innovation and Crisis Response: Green's leadership saw the company drive innovations, particularly in supporting global vaccine delivery during the COVID-19 pandemic, showcasing West's adaptability and market impact during crises.
- Future Outlook: With over 10,000 employees and 25 manufacturing facilities worldwide, West generated $3.07 billion in net sales in fiscal year 2025, demonstrating its leadership in high-quality injectable solutions and positioning for continued value creation.
See More
